Ensaios Clínicos em Fase de Recrutamento

Atualmente, estão em fase de recrutamento para realização no Hospital da Luz os seguintes ensaios clinicos:

  • Ensaios clínicos na área da degenerescência macular

    • Ensaio clínico AZURE

    An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neovascular age-related macular degeneration (nAMD).

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000120-33/PT


  • Ensaios clínicos na área da diabetes

    • Ensaio clínico FIGARO

    A randomized, double-blind, placebo-controlled, parallel-group, multicenter, event-driven Phase III study to investigate the efficacy and safety of finerenone on the reduction of cardiovascular morbidity and mortality in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic kidney disease in addition to standard of care

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-000950-39/PT

  • Ensaios clínicos na área da esclerose múltipla

    • Ensaio Clínico PLENO

    Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients with Relapsing Remitting Multiple Sclerosis (MS) Transitioning from Current Subcutaneous Interferon Therapy to Peginterferon Beta 1a (PLEGRIDY™)

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000434-21/PT

  • Ensaios clínicos na área da endometriose

    • SPIRIT 1

    An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered with and without Low-Dose Estradiol and Norethindrone Acetate in Women with Endometriosis-Associated Pain

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-001588-19/PT

  • Ensaios clínicos na área das nevralgias herpéticas

    • Ensaio clínico EMPHENE

    A double-blind, placebo-controlled, randomized dose ranging trial to determine the safety and efficacy of three dose levels of EMA401 in reducing 24-hour average pain intensity score in patients with post-herpetic neuralgia

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-000280-16/PT


  • Ensaios clínicos na área do adenocarcinoma do pâncreas

    • Ensaio Clínico CanStem111P

    A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma.

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-004359-57/PT

  • Ensaios clínicos na área do carcinoma da mama

    •  Ensaio clínico OLYMPIA

    A randomised, double-blind, parallel group, placebo-controlled multi-centre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-003839-30/PT

    • Ensaio clínico PALLAS:

    A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005181-30/PT





  • Ensaios clínicos na área do carcinoma da próstata

  • Ensaios clínicos na área do carcinoma do pulmão

    • Ensaio clínico M16-298 MERU

    “A Randomized, Double-Blind, Placebo-Controlled Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects with Extensive Stage Small Cell Lung Cancer (MERU)”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003503-64/PT

    • Ensaio clínico M16-289 TAHOE

    “A Randomized, Open-Label, Multicenter, Phase 3 Study of Rovalpituzumab Tesirine Compared with Topotecan for Subjects with Advanced or Metastatic DLL3high Small Cell Lung Cancer (SCLC) who have First Disease Progression During or Following Front-Line Platinum-Based Chemotherapy”

    Para mais informações: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003726-17/PT


  • Ensaios clínicos na área do tromboembolismo pulmonar

    • Ensaio clínico Hot PE

    “Home treatment of patients with low-risk pulmonary embolism with the oral factor xa inhibitor rivaroxaban: prospective management trial”

    Para mais informações:


  • Ensaios clínicos na área da insuficiência cardíaca

    • Ensaio Clínico GALACTIC-HF

    A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Reduced Ejection Fraction

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-002299-28/PT

    • Ensaio clínico LCZ696D2302

    A 24-week, randomized, double-blind, multi-center, parallel group, active controlled study to evaluate the effect of LCZ696 on NT-proBNP, symptoms, exercise function and safety compared to individualized medical management of comorbidities in patients with heart failure and preserved ejection fraction

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2016-003410-28/PT

    • Ensaio Clínico VITALITY HFpEF

    A randomized parallel-group, placebo-controlled, double-blind, multi-center trial to eValuate the effIcacy and safeTy of the orAL sGC stImulator vericiguaT to improve phYsical functioning in activities of daily living in patients with heart failure and preserved ejection fraction (VITALITY-HFpEF)

    Mais informações em: https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-000298-65/PT



Se estiver interessado em saber mais sobre algum dos ensaios clínicos referidos, poderá enviar um e-mail para ensaiosclinicos.lisboa@hospitaldaluz.pt e a equipa do Centro de Investigação Clínica do Hospital da Luz entrará em contacto consigo.

O envio deste e-mail não é garantia da participação num ensaio clínico.